WW · WW International, Inc.

WW International reported Q1 2026 results showing resilience amid challenges, with total revenue of $168 million reflecting a 10% year-over-year decline driven by Behavioral revenue falling to $129 million from $156 million due to secular headwinds in the Core tier and international markets post-Chapter 11 reorganization. However, Clinical Subscription Revenue surged 32% to $39 million, supported by End of Period Clinical Subscribers reaching 197 thousand, up 46% YoY and 51% sequentially, despite lapping prior-year growth from the discontinued compounded semaglutide offering. Core+ subscribers within Behavioral grew 6% YoY to 537 thousand, aiding a 13% increase in Monthly Subscription ARPU to higher-value tiers like Med+ and Core+. Gross margins remained robust at 70.5% (GAAP) and 73.6% (Adjusted), near record highs, bolstered by operational efficiencies offsetting the mix shift to lower-margin Clinical products. The Q1 Adjusted EBITDA loss of $1.8 million reflected peak-season marketing investments, a narrower loss than the prior year's $26.9 million profit, while Net Loss improved to $52.0 million partly due to Fresh Start Accounting impacts. Management, led by Interim Office of the Chief Executive members Jon Volkmann and Felicia DellaFortuna, expressed confidence in the strategy blending Clinical growth with Behavioral stabilization, highlighting integrations like expanded Novo Nordisk collaborations for affordable GLP-1 access. The company reaffirmed FY2026 guidance for $620-$635 million revenue and $105-$115 million Adjusted EBITDA, expecting sequential improvements. Balance sheet actions include a fully subscribed debt prepayment using $37 million cash to reduce term loan principal by $42 million in Q2, cutting annualized interest expense by ~$4 million at the 10.51% rate, enhancing liquidity from $121 million cash position to support transformation.